HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yosuke Ishii Scott M. Goldman Richard B. Schuessler Ralph J. Damiano, Jr Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ishii, Y. Articles by Damiano, R. J. Search for Related Content PubMed PubMed Citation Articles by Ishii, Y. Articles by Damiano, R. J., Jr Related Collections Coronary disease

Ann Thorac Surg 2007;83:517-525
© 2007 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Novel Bioengineered Small Caliber Vascular Graft With Excellent One-Month Patency

^a Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri
^b Kensey Nash Corp, Exton, Pennsylvania
^c American Registry of Pathology, Washington, DC

Accepted for publication September 7, 2006.

^_* Address correspondence to Dr Damiano, Suite 3108, Queeny Tower, Barnes-Jewish Hospital Plaza, St. Louis, MO 63110 (Email: damianor{at}wustl.edu).

Presented at the Poster Session of the Forty-first Annual Meeting of The Society of Thoracic Surgeons, Tampa, FL, Jan 24–26, 2005.

BACKGROUND: A bioengineered microporous polycarbonate-siloxane polyurethane graft has been developed for coronary artery bypass grafting. Biological agents can be impregnated into its absorbable collagen and hyaluronan microstructure and stable macrostructure to promote patency. The objective of this study was to examine the biological performance and biomechanical characteristics of this graft.

METHODS: Heparin-sirolimus (HS) or heparin-sirolimus–vascular endothealial growth factor (HSV) grafts were manufactured for this study. Heparin (40 U) was embedded in the microstructure of the graft for early elution from the graft wall. Heparin (100 U) and sirolimus (450 µg) were incorporated into the macrostructure of the graft for late elution. Vascular endothelial growth factor was also embedded in the microstructure of the graft. Both grafts (3.6 mm internal diameter, 24 mm length) were implanted into the abdominal aortas of rabbits (n = 36) to compare with heparin-alone (H) grafts (n = 9). At 4 hours, 1 day, and 1, 2, and 4 weeks after surgery, the grafts were removed for histologic, immunohistochemical, and biomechanical evaluations.

RESULTS: The patency rate of all grafts was 100% at each time point. None of grafts had stenosis after surgery. Endothelial cells were observed at 4 weeks after surgery in the HS, HSV, and H grafts. Although there was no significant difference of neointima thickness among the HS, HSV, and H grafts (136 ± 75, 93 ± 64, and 125 ± 90 µm; p = 0.08), the H grafts did have more cellular infiltration in the graft than the HS or HSV grafts. There was neocapillary formation inside the graft wall at 4 weeks in all grafts. The graft macrostructure was unchanged based on biomechanical evaluation 4 weeks after surgery.

CONCLUSIONS: A unique drug-eluting graft had excellent patency at 1 month and may encourage luminal endothelialization without excessive intimal hyperplasia. Although vascular endothelial growth factor did not improve intimal formation, cell infiltration, or vascularization, sirolimus might inhibit cell proliferation. Further long-term study would need to evaluate the efficacy of impregnated sirolimus.